An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to investigate whether topical application of a cromolyn sodium solution is able to decrease the facial redness seen in patients with papulopustular rosacea. Previous work in the lab of Dr. Di Nardo on mice has suggested that cromolyn may be able to have this effect. The study will enroll a total of 10 patients. 5 will randomly be assigned to receive the cromolyn sodium solution, and the other 5 will be randomly assigned to receive the placebo solution. All participants will be instructed to apply their assigned solution twice daily to their face. Patients will return to the clinic 3, 6, and 8 weeks after the distribution of the solutions to measure the efficacy of their assigned solution.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Cromolyn Sodium; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Subject is male or non-pregnant female, 18 - 80 years of age.

• Subjects willing and able to give informed consent.

• Subjects willing and able to comply with the requirements of the study.

• Subject has the clinical diagnosis of at least mild erythema.

• Subject has been on a stable dose for greater than 3 months of medications for treatment of concurrent medical condition (including oral contraceptive pills, vasodilators, adrenergic blocking agents) OR the investigator has determined that the medications are unlikely to affect the patient's rosacea and/or treatment during the study

• Subject is in general good health in the opinion of the investigator.

Exclusion Criteria:

• Subject has a diagnosis of Steroid Rosacea or Pyoderma Faciale (rosacea fulminans)

• Subject has a history of Carcinoid, Pheochromocytoma, Serotonin Syndrome or other systemic flushing causes.

Subject has used facial topical therapies (OTC drug products or prescription products) for any reason within the prior 28 days

• Subject has used systemic corticosteroid or systemic antibiotics (especially doxycycline, minocycline, tetracycline, metronidazole) within the prior 28 days.

• Subject has had laser or light-based treatment for rosacea within the prior 3 months.

• Subject has had systemic retinoids and retinoid derivatives over the past 6 months

• Subject has any history of renal or hepatic insufficiency.

• Subject has a known hypersensitivity or allergy to Cromolyn sodium or components of the vehicle.

• Subject is pregnant or lactating or planning a pregnancy during the duration of the study

• Subject has been treated with another investigational device or drug within 28 days prior to study enrollment or intends to participate in a clinical trial concurrent with this study

• Subject has clinically significant findings, medical history or conditions (other than rosacea), which in the opinion of the Investigator may compromise the study, treatment protocol, or safety of the patient or treatment allocation.

Subject has a known hypersensitivity or allergy to tape or other adhesive materials